These B cells must express MHC class II and co-stimulatory molecules, like B7.1 and B7.2 [17–19]. Presumably, this helps to recruit and trigger regulatory T cells that express

CD25 AZD6244 in vitro via binding to CTLA-4 [14,16,18]. Finally, we propose that the IgG carrier in our construct plays an important role by directing the trafficking and processing of the fusion protein and by presentation of regulatory epitopes within the IgG [19]. Our basic protocol is shown in Fig. 2. The success of this approach in a number of models is summarized in Table 1 below. After proof of principle with model peptides and multi-epitope antigens [7,8], we first targeted experimental autoimmune uveitis in collaboration with the Caspi lab at the NIH. Posterior uveitis is ocular inflammatory disease that is

an important contributor to blindness in humans. Current treatment involves primarily the use of steroids and immunosuppressive drugs, with undesirable long-term side effects that make gene therapy a viable future treatment option. In the mouse model, we inserted the major pathogenic epitope (residues 161–180) of interphotoreceptor retinoid-binding protein (IRBP) into the IgG heavy chain backbone of our retroviral vector. Mice given retrovirally transduced B cells expressing IRBP were significantly protected from disease compared to control groups receiving B cells expressing an unrelated antigen [9]. Similar results were obtained with the soluble selleck products retinal antigen, SAG, in rats [10]. Our system was extended next to experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis,

an autoimmune inflammatory disorder of the central nervous system. Three different target antigens have been used to induce EAE, myelin basic protein (MBP), proteolipid protein (PLP) or myelin oligodendrocyte glycoprotein (MOG), each of which reflects epitopes, which mimic different forms of the human disease. We engineered each of these antigens into our retroviral vector and used transduced B cells in both prophylactic and therapeutic models of EAE. In all three models, we found that recipients of transduced B cells or bone marrow Lepirudin cells were protected from EAE in terms of clinical score and T cell responses [11–13]. Similar results with MBP as the target antigen were demonstrated by Chen et al. using a different construct in LPS B cells [20,21]. In a model for type I diabetes, the NOD female mouse, we have used two of the major islet target antigens, (pro)insulin and glutamic acid decarboxylase (GAD65), engineered into our IgG fusion construct. NOD females spontaneously develop insulitis and hyperglycaemia beginning stochastically at 10–12 weeks of age. By 6 months of age, virtually all mice are diabetic.